Analyzing Generics Market in Germany 2017

  • ID: 4377333
  • Report
  • Region: Germany
  • 95 Pages
  • Aruvian's R'search
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Mylan N.V.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • MORE

Germany has a historical reputation as being a global leader in the pharmaceutical industry, being the headquarters of many global stalwarts such as Bayer, BASF, STADA, etc. The German pharmaceutical industry enjoys stability and therefore, it comes as no surprise that the generic drugs sector in Germany has also had a stable growth in recent years. Generic medicines contribute significantly to the German drug supply and the government has been making all efforts to further boost this sector with attractive pricing and innovations. In fact, in 2015, the volume share of generic drugs in Germany was over 75%, much higher than the share in European countries.

In 2016, the German generics sector comfortably crossed revenues of USD 8 billion and is expected to reach a value of nearly USD 9.5 billion by the end of 2021. As many generic drugs come off patent, the German generic industry is poised to take advantage of this situation and post further growth in coming years.

Analyzing Generics Market in Germany 2017 - a comprehensive coverage of the German generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.

Moving on, we analyze the Generics Industry in Europe through the same parameters.

The Generics Industry in Germany is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.

We also include a Porter’s Five Forces analysis of the German Generics Industry. Generics pricing and reimbursement situation in Germany and trends and challenges facing the industry are analyzed.

Analysis of the major industry players in the German generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include STADA, Mylan, Sandoz International, Teva Pharmaceutical Industries and others.

This research report helps you get an insider’s look at the German generic industry and helps you understand what the future holds for the industry. Regulatory framework, pricing and reimbursement scenarios, comparison of the German market with its regional counterparts, all these data points makes this report an essential resource for analytical purposes.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Mylan N.V.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • MORE

A. Executive Summary

B. Analyzing the Global Generics Industry
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value & Volume Analysis
B.4 Industry Segmentation by Geography
B.5 Patent Expiries
B.6 Global Generic Industry Structure
B.7 Industry Forecast

C. Generics Industry in Europe
C.1 Industry Overview
C.2 Industry Value & Volume
C.3 Industry Segmentation by Geography
C.4 Industry Forecast

D. Generics Industry in Germany
D.1 Industry Overview
D.2 Industry Value & Volume
D.3 Industry Segmentation by Geography
D.4 Regulatory Framework
D.5 Industry Forecast

E. Generics Industry in Germany: Porter’s Five Forces Strategy Analysis
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes

F. Pricing & Reimbursement in Germany
F.1 Overview
F.2 Generics Pricing & Reimbursement Scenario
F.3 Trends & Challenges

G. Major Industry Players
G.1 Allergan Plc
G.1.1 Corporate Analysis
G.1.2 Financial Analysis
G.1.3 SWOT Analysis
G.2 Aspen Pharmacare Holdings Ltd
G.2.1 Corporate Analysis
G.2.2 Financial Analysis
G.2.3 SWOT Analysis
G.3 Mylan N.V.
G.3.1 Corporate Analysis
G.3.2 Financial Analysis
G.3.3 SWOT Analysis
G.4 STADA Arzneimittel AG
G.4.1 Corporate Analysis
G.4.2 Financial Analysis
G.4.3 SWOT Analysis
G.5 Teva Pharmaceutical Industries Limited
G.5.1 Corporate Analysis
G.5.2 Financial Analysis
G.5.3 SWOT Analysis
G.6 Sandoz International GmbH

H. Glossary of Terms

List of Figures
Figure 1: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
Figure 2: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Figure 3: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Figure 4: Global Generics Market Segmentation by Geography (%), 2016
Figure 5: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
Figure 6: Market Share of Leading Generic Companies Worldwide (%), 2016
Figure 7: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
Figure 8: Global Generics Industry Forecast (in USD Billion), 2016-2021
Figure 9: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2016-2021
Figure 10: Value of the European Generics Market (in USD Billion), 2012-2016
Figure 11: Volume Growth of the European Generics Market (%), 2012-2016
Figure 12: Share of the European Generics Industry by Countries (%), 2016
Figure 13: Forecast of the European Generics Market (in USD Billion), 2016-2021
Figure 14: Volume Forecast of the European Generics Market (%), 2016-2021
Figure 15: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Figure 16: Volume Growth of the Generics Market in Germany (%), 2012-2016
Figure 17: Share of Germany in the European Generics Industry (%), 2016
Figure 18: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Figure 19: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Figure 20: Porter's Five Forces Strategy Analysis of the Generics Industry in Germany
Figure 21: Bargaining Power of Buyers in the German Generics Industry
Figure 22: Bargaining Power of Suppliers in the German Generics Industry
Figure 23: Competitive Rivalry in the German Generics Industry
Figure 24: Threat of New Entrants to the German Generics Industry
Figure 25: Threat of Substitutes to the German Generics Industry
Figure 26: Revenues & Profitability of Allergan Plc (in USD Million), 2011-2015
Figure 27: Revenues & Profitability of Aspen Pharmacare (in USD Million), 2011-2015
Figure 28: Revenues & Profitability of STADA Arzneimittel AG (in USD Million), 2011-2015
Figure 29: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2011-2015

List of Tables
Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2012-2016
Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2012-2016
Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2016
Table 4: Global Generics Industry Forecast (in USD Billion), 2016-2021
Table 5: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2016-2021
Table 6: Value of the European Generics Market (in USD Billion), 2012-2016
Table 7: Volume Growth of the European Generics Market (%), 2012-2016
Table 8: Share of the European Generics Industry by Countries (% & USD Billion), 2016
Table 9: Forecast of the European Generics Market (in USD Billion), 2016-2021
Table 10: Volume Forecast of the European Generics Market (%), 2016-2021
Table 11: Value of the Generics Market in Germany (in USD Billion), 2012-2016
Table 12: Volume Growth of the Generics Market in Germany (%), 2012-2016
Table 13: Share of Germany in the European Generics Industry (% & USD Billion), 2016
Table 14: Implications of the Price Freeze
Table 15: Forecast of the Generics Market in Germany (in USD Billion), 2016-2021
Table 16: Volume Forecast of the Generics Market in Germany (%), 2016-2021
Table 17: Key Financials of Allergan Plc (in USD Million), 2011-2015
Table 18: Key Financials of Aspen Pharmacare (in USD Million), 2011-2015
Table 19: Key Financials of STADA Arzneimittel AG (in USD Million), 2011-2015
Table 20: Key Financials of Teva Pharmaceutical (in USD Million), 2011-2015

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Aspen Pharmacare Holdings Ltd
  • Mylan N.V.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll